Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aili eye drops are an ophthalmic pharmaceutical product primarily used for the treatment of dry eye syndrome and related conditions. Its active ingredient, sodium hyaluronate, is a naturally occurring biopolymer that forms a stable and long-lasting moisture film on the ocular surface. This film helps to protect the eye, increase the stability and volume of the pre-corneal tear film, and promote the repair of corneal epithelial cells. Developed and manufactured by Santen Pharmaceutical, Aili eye drops are administered topically to the eye.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Aili.